Search  Search
Font Size:     Small text Medium text Large text   email pageemail pageprint pageprint page

National Joint Registry - leading example of a clinical registry

20 June 2012

The House of Commons (HoC) Science and Technology Committee held their second evidence session on 13 June 2012, as part of its inquiry into the 'Regulation of medical implants.'

During the first panel, the National Joint Registry (NJR) was cited by witnesses as an 'asset' for the country in 'ensuring patient safety' as part of post-market surveillance for implantable devices. The NJR, established in 2003, collects data on hip, knee, ankle, elbow and shoulder joint replacements and data collection has been mandatory for NHS and independent hospital since April 2011.

In the concluding and third panel, the registry is recognised as giving greater 'public visibility to accumulating experience' and offering transparent information on outcomes, through its Annual Report, which has been a 'valuable resource in changing clinical practice' particularly in respect of concerns for metal-on-metal hip replacements. Additionally, the NJR is outlined as an example of how transparency, around the outcomes of joint replacement surgery, is a model for other areas.

"The NJR is pleased to be recognised as a leading example of a clinical register and an example of why device registers are a critical part of post-market surveillance and protecting patient safety. As the largest registry of its kind in the world with a mature data set (at seven years), we will continue to grow and monitor outcomes from joint replacement surgery for the benefit of patients and clinicians. We are continually exploring new ways of sharing this information, to improve transparency and drive better care" said NJR Lead Elaine Young.

Panel witnesses for the HoC Science and Technology Committee session on 13 June 2012 were:

  1. John Howlett, British Standards Institute and Peter Ellingworth, Association of British Healthcare Industries (ABHI)
  2. Jacqueline Minor, Director of Consumer Affairs, European Commission
  3. Sir Kent Woods, Chief Executive of Medicines and Healthcare products Regulatory Agency (MHRA) and Lord Howe, Parliamentary Under-Secretary of State for Quality, Department of Health

The first evidence session took place on 23 May 2012 and heard the perspective of clinicians, patients and scientists.

References specific to the National Joint Registry:

  • 9:37:40 onwards
  • 10:10:05 onwards
  • 11:03:01 onwards
  • 11:26:09 onwards

(If the video fails to display or displays incorrectly, please click here to see the recording.)


Click here to visit the HOC Science and Technology Committee page >

Please see further information from the House of Commons Science and Technology Committee using this link >


Copyright © 2020 National Joint Registry Terms and conditions Privacy policy Login